Loading...
XTAE
EFNC-M
Market cap2mUSD
Aug 15, Last price  
261.30ILS
Name

Erech Finance Cahalacha Ltd

Chart & Performance

D1W1MN
XTAE:EFNC-M chart
P/E
P/S
23.51
EPS
Div Yield, %
Shrs. gr., 5y
15.94%
Rev. gr., 5y
-50.83%
Revenues
282k
-97.35%
121,000571,000195,00083,00040,0009,808,0006,592,00010,070,00013,390,00010,649,000282,000
Net income
-25m
L+1.01%
-28,276,000-47,339,000-15,766,000-8,947,000-7,014,000-10,300,000-6,779,0001,345,0001,024,000-25,040,000-25,293,000
CFO
-2m
L-53.88%
-22,227,000-40,309,000-20,561,000-9,994,000-7,681,000-330,000532,000-6,791,000-8,952,000-4,716,000-2,175,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Erech Finance Cahalacha Ltd, including its subsidiaries, provides diverse lending and credit solutions to small and medium-sized businesses, associations, and individual clients across Israel. The company's operations are structured into two main divisions: Non-Bank Credit and Biomed Drug. Additionally, Erech Finance Cahalacha Ltd is engaged in pharmaceutical research and development, concentrating on treatments for diabetes and cancer. Its corporate headquarters are located in Jerusalem, Israel.
IPO date
Aug 04, 2010
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT